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Antimicrobial drug use is a key driver of the pro-motion and transmission of antimicrobial resis-
tance in humans, livestock, and companion animals 
(e.g., dogs, cats) (1–5). Of these groups, the role of 
companion animals in the development (1,2), car-
riage, (6) and transmission of antimicrobial-resistant 
bacteria among animal and human populations is be-
ing increasingly realized, partly because of the close 
proximity in which these animals reside with humans 
(5,7,8). Indeed, companion animals are now included 
in recent global action plans aimed at tackling the 
global health threat of antimicrobial resistance (9).
In human medicine, electronic health records 
(EHRs) and qualitative research techniques have 
been used extensively to identify practitioner- and 
patient-led factors associated with the likelihood of 
antimicrobial drug prescription (10–13). In veterinary 
medicine, studies investigating antimicrobial drug 
prescribing practices and related risk factors are more 
limited (14). Companion animal research has largely 
focused on postal surveys (15,16) and in-person inter-
views (17) to explore perceptions held by veterinary 
practitioners. However, recent advances in veterinary 
health informatics have provided opportunities for 
widescale use of veterinary EHRs to survey antimi-
crobial prescription (18,19).
Thus far, key insights into antimicrobial prescrip-
tion frequency and variety have been demonstrated 
(20–23), including an apparent increased use of cefo-
vecin in cats (21,22); the World Health Organization 
considers this third-generation cephalosporin to be 
a highest priority critically important antimicrobial 
(HPCIA) (24). Considerable interpractice (20,22), re-
gional (21), and clinical presentation (22,25,26) vari-
ability in antimicrobial drug prescription frequency 
and choice has also been identified. Although previ-
ous studies have indicated divergence of veterinary 
opinion over when antimicrobial therapy is justified 
and which classes of antimicrobial drugs would be 
most appropriate (15–17), the reasons why such vari-
ation exists are unknown.
To identify factors potentially influencing antimi-
crobial prescribing in the clinical environment, we an-
alyzed EHRs for a large, diverse population of dogs 
and cats, collected from a network of volunteer first-
opinion (general) veterinary practices across Great 
Britain (England, Scotland, and Wales). We explored 
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Antimicrobial stewardship is a cornerstone of efforts to cur-
tail antimicrobial resistance. To determine factors potential-
ly influencing likelihood of prescribing antimicrobials for ani-
mals, we analyzed electronic health records for unwell dogs 
(n = 155,732 unique dogs, 281,543 consultations) and cats 
(n = 69,236 unique cats, 111,139 consultations) voluntarily 
contributed by 173 UK veterinary practices. Using multivari-
able mixed effects logistic regression, we found that factors 
associated with decreased odds of systemic antimicrobial 
prescription were client decisions focused on preventive 
health: vaccination (dogs, odds ratio [OR] 0.93, 95% CI, 
0.90–0.95; cats, OR 0.92, 95% CI 0.89–0.95), insurance 
(dogs, OR 0.87, 95% CI 0.84–0.90; cats, OR 0.82, 95% 
CI 0.79–0.86), neutering of dogs (OR 0.90, 95% CI 0.88–
0.92), and practices accredited by the Royal College of Vet-
erinary Surgeons (OR 0.79, 95% 95% CI 0.68–0.92). This 
large multicenter companion animal study demonstrates 
the potential of preventive healthcare and client engage-
ment to encourage responsible antimicrobial drug use.
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associations between antimicrobial prescription (in-
cluding antimicrobials authorized for systemic ad-
ministration, antimicrobials authorized for topical 
administration, and HPCIAs) and a range of veteri-
nary practice, practitioner, client, and animal-related 
factors (including socioeconomic factors and preven-
tive healthcare interventions) for animals presented 
primarily for investigation of disease.
Materials and Methods
Data Collection
For this cross-sectional study, we examined EHRs 
from 178 volunteer veterinary practices (386 unique 
sites) taking part in the Small Animal Veterinary Sur-
veillance Network (SAVSNET; University of Liver-
pool, Liverpool, UK; ethical approval reference no. 
RETH000964), by using the Robovet practice man-
agement system (Covetrus, https://www.covetrus.
com). We retrieved EHRs from booked consultations 
(19) from April 1, 2014, through March 31, 2016. Each 
consultation record included patient species, breed, 
sex, neuter status, insurance status, microchip sta-
tus, vaccination history, date of birth, client’s postal 
code, and any products dispensed at time of consulta-
tion. Every consultation record was further classified 
by the attending veterinary professional into 1 of 10 
main presenting complaints (categorized as healthy, 
unhealthy, or postoperative), indicating the main rea-
son the animal was presented to the veterinary prac-
tice, as previously described (22).
Data Management
General Data Management
Initially available were consultations for 762,648 dogs 
and 300,606 cats. We excluded animals for whom 
dates of birth were probably incorrectly recorded 
(i.e., 1,577 dogs recorded as >24.5 years and 2,467 cats 
as >26.0 years of age at consultation) and animals for 
whom a valid client postal code was lacking (23,705 
dogs, 9,901 cats). We included only consultations in 
which animals were recorded as unhealthy (sick ani-
mal consultations) according to main presenting com-
plaint (MPC) (282,263 of 737,366 remaining dog and 
111,367 of 288,238 remaining cat consultations). We 
also excluded 5 veterinary practices that provided in-
sufficient EHRs (<50 consultations) for adequate sta-
tistical analyses. 
Using a semiautomated rule-based text-mining 
method as previously described (22), we identified 
antimicrobial prescription via the text-based prod-
uct description and classified use as systemic (oral or 
injectable) or topical (topical, aural, ocular). 
All fluoroquinolones, macrolides, and third-genera-
tion cephalosporins were considered HPCIAs (24). 
We compiled a list of antimicrobials authorized 
for use in dogs or cats use in the United Kingdom 
(Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/26/8/19-1786-App1.pdf).
Animal Factors
Animals were considered vaccinated if the most re-
cently recorded vaccination date (disregarding vac-
cine composition) was <3.5 years (broadly reflective 
of current vaccine interval guidelines) before the rele-
vant consultation date (27). Breeds were summarized 
according to standardized breed terms (28) before 
being categorized into either genotypically similar 
breed groups (29), crossbreeds, breeds not yet geneti-
cally classified (unclassified), or breed not recorded/
recognizable (unknown).
Client Factors
Using clients’ home postal code, we assigned a mea-
sure of predicted deprivation to each client accord-
ing to the most recent Indices of Multiple Depriva-
tion (IMD): England 2015 (https://www.gov.uk/
government/statistics/english-indices-of-depriva-
tion-2015), Scotland 2012 (https://www2.gov.scot/
Topics/Statistics/SIMD/DataAnalysis/Background-
Data-2012), and Wales 2014 (https://statswales.gov.
wales/Catalogue/Community-Safety-and-Social-
Inclusion/Welsh-Index-of-Multiple-Deprivation/Ar-
chive/WIMD-2014). Because IMD measures between 
countries are not directly comparable, country was 
included in statistical models as a 3-level factor, and 
each country’s complete set of IMD ranks was res-
caled to the range of 0 to 1, with 1 corresponding to 
the least deprived area.
We determined country of residence and urban/
rural status by referring to the National Statistics 
Postcode Look-up (https://geoportal.statistics.gov.
uk/datasets/4f71f3e9806d4ff895996f832eb7aacf). The 
recorded centroid associated with each postal code 
was used to place each client within a 1-km2 gridded 
cell, and each EHR was hence associated with an esti-
mate of the number of dogs or cats within each 1-km2 
gridded cell as defined by Aegerter et al. (30).  We 
then used postal code district to provide an estimate 
of the number of dogs or cats per household for each 
recorded postal code (30).
Veterinary Practice and Practitioner Factors
We used the Royal College of Veterinary Surgeons 
(RCVS) Practice Register (https://findavet.rcvs.org.
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uk/home, accessed 2016 Oct 18) to summarize each 
veterinary practice into 4 categories of advertised 
species treated: companion animal; mixed (compan-
ion animal, large animal, and equine); companion 
and large animal; and companion animal and equine. 
Practices were considered accredited under the vol-
untary RCVS Practice Standards Scheme if >1 site 
was recorded as accredited (Core Standards, General 
Practice, or Veterinary Hospital), and as an RCVS 
Veterinary Hospital if the practice contained a veteri-
nary hospital site. We also recorded practices listing 
referrals as an interest and practices employing >1 
veterinary surgeon holding RCVS Advanced Veteri-
nary Practitioner status or separate RCVS Specialist 
status in areas of relevance to companion animals.
Statistical Analyses
We used R (https://www.r-project.org) for all anal-
yses. Descriptive proportions and 95% CIs were 
adjusted for clustering within sites (bootstrap meth-
od, n = 5,000 samples). Using the R package lme4 
(https://cran.r-project.org/web/packages/lme4/
index.html), we fitted univariable and multivariable 
mixed effects logistic regression models separate-
ly for dogs and cats. Because likelihood ratio tests 
(LRTs), the Akaike Information Criterion (AIC), the 
Bayesian Information Criterion (BIC), and evidence 
of interpractice antimicrobial prescription frequency 
variation (22) indicated that observations were clus-
tered within veterinary practice, site, and animal, we 
therefore included all 3 factors as random intercepts 
in all models. We conducted separate analyses to as-
sess the association between explanatory variables 
and 3 binary outcomes of interest: antimicrobial 
prescription authorized for systemic administra-
tion (systemic antimicrobial), topical administration 
(topical antimicrobial), and systemically adminis-
tered HPCIAs.
Initial univariable screening included 15 categori-
cal variables (sex, neutered status, microchip status, 
insurance status, vaccination status, genetic breed 
group, country of residence, client urban/rural status, 
main presenting complaint, treated species [practice 
type], RCVS accreditation, RCVS Veterinary Hospital, 
referral interest, RCVS Advanced Veterinary Practice, 
and RCVS specialist), and 4 continuous variables (age 
at consultation, rescaled IMD [rIMD] rank, dog or cat 
population per square kilometer, and mean number 
of dogs or cats per household at district of residence). 
For continuous explanatory variables, we included 
up to cubic polynomial terms if an LRT, AIC, and 
BIC indicated significantly improved fit, compared 
with linear and lesser polynomial terms. Explanatory 
variables were retained for multivariable analysis if 
an LRT indicated p<0.20 against a null model.
To minimize AIC and BIC, we conducted man-
ual stepwise backward elimination on multivariable 
models. A 2-way interaction between rIMD and the 
3-level factor country was included in the initial mul-
tivariable model (and were deleted if AIC and BIC 
decreased); country alone was a false intercept. Con-
founding was accounted for by assessing effect varia-
tion upon removal of variables. Two-way interaction 
terms between other explanatory variables were as-
sessed by using AIC, BIC, and an LRT. The variance 
inflation factor was used to assess multicollinear-
ity (https://CRAN.R-project.org/package=car). For 
continuous variables, projected prescription prob-
abilities and associated 95% CIs were calculated from 
log odds by using sjPlot (https://cran.r-project.org/
web/packages/sjPlot/index.html). Statistical signifi-
cance was defined as p<0.05.
Results
Analyzed data were from 281,543 consultations for 
sick dogs (155,732 unique dogs) and 111,139 sick cats 
(69,236 unique cats) from 173 veterinary practices (379 
sites). A descriptive population summary is shown in 
Table 1, and a summary of genetic breed groups in-
cluded in this study is shown in Appendix Table 2.
Dogs
Prescription of Antimicrobial Drugs
Systemic antimicrobial drugs were prescribed dur-
ing 25.7% (95% CI 24.9%–26.6%) of consultations, 
topical antimicrobials during 14.2% (95% CI 13.9%–
14.6%), and systemic HPCIAs during 1.4% (95% CI 
1.2%–1.6%). The most commonly prescribed class 
of systemic HPCIAs was fluoroquinolones (0.9% of 
sick animal consultations, 95% CI 0.7%–1.0%), fol-
lowed by third-generation cephalosporins (0.5%, 
95% CI 0.4%–0.6%) and macrolides (0.1%, 95% CI 
0.0%–0.2%). Antimicrobial prescription summa-
rized according to common consultation by breed is 
shown in Appendix Table 3.
Prescription of Systemic Antimicrobial Drugs
Descriptive analyses and univariable model results 
are summarized in Appendix Table 4. Final multivari-
able model results are available in Table 2. Systemic 
antimicrobial drugs were less likely to be prescribed 
for vaccinated or neutered dogs than for nonvac-
cinated or non-neutered dogs. Systemic antimicro-
bial drugs were also less likely to be prescribed for 
insured dogs up to ≈12 years of age (Figure 1, panel 
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A). Odds for prescription of a systemic antimicrobial 
drug were greater for dogs with an MPC that was 
respiratory than for those with a gastroenteric MPC. 
Mixed practices were associated with significantly 
increased odds of this prescription compared with 
practices treating companion animals only. RCVS-
accredited practices were less likely to prescribe a 
systemic antimicrobial.
Prescription of Systemic HPCIAs
Descriptive analyses and univariable model results 
are summarized in Appendix Table 5. Final multi-
variable model results are available in Table 3. Sys-
temic HPCIAs were less likely to be prescribed for 
vaccinated or insured dogs; highest odds for pre-
scription were for dogs with a respiratory MPC. Odds 
increased with age (Figure 2, panel A). In terms of 
genetic breed, the greatest odds of systemic HPCIA 
prescription were for the toy breed group, compared 
with retrievers.
Prescription of Topical Antimicrobial Drugs
Descriptive analyses and univariable model results 
are summarized in Appendix Table 6. Final multivari-
able model results are available in Table 4 (https://
wwwnc.cdc.gov/EID/article/26/8/19-1786-T4.htm). 
Topical antimicrobial drugs were less likely to be pre-
scribed for insured dogs, although odds increased sig-
nificantly for male, microchipped, or vaccinated dogs. 
The effect of age varied according to MPC; an MPC of 
pruritus was generally associated with greatest odds 
of topical antimicrobial drug prescription throughout 
life, broadly decreasing with increased age (Figure 3, 
panel A). Odds of topical antimicrobial drug prescrip-
tion were lowest for sight hounds compared with re-
trievers. Practices employing RCVS specialists were 
less likely to prescribe a topical antimicrobial.
Cats
Prescription of Antimicrobial Drugs
Systemic antimicrobial drugs were prescribed dur-
ing 32.9% (95% CI 31.9–33.8) of consultations, topi-
cal antimicrobials during 6.1% (95% CI 5.9–6.3), 
and systemic HPCIAs during 17.3% (95% CI 16.2–
18.4). The most commonly prescribed class of sys-
temic HPCIA was third-generation cephalosporins 
(16.4% of consultations for sick cats, 95% CI 15.3–
17.6), followed by fluoroquinolones (0.7%, 95% CI 
0.4–0.9) and macrolides (0.03%, 95% CI 0.0–0.05). 
Antimicrobial prescription summarized accord-
ing to common consultation by breed is shown in 
Appendix Table 7.
Prescription of Systemic Antimicrobial Drugs
Descriptive analyses and univariable model results 
are summarized in Appendix Table 8. Final multivari-
able model results are available in Table 5. Odds of 
systemic antimicrobial prescription were significant-
ly reduced for vaccinated or insured cats. Odds were 
highest for cats with respiratory and trauma MPCs, 
although there was a significant interaction between 
sex and MPC; male cats presented for trauma were 
significantly more likely than female cats to receive 
an antimicrobial prescription. Systemic antimicrobial 
drugs were also less likely to be prescribed for female 
cats up to ≈15 years of age, when odds for female 
cats exceeded those for male cats (Figure 1, panel b). 
Mixed practices were more likely than practices treat-
ing companion animals only to prescribe a systemic 
antimicrobial drug.
Prescription of Systemic HPCIA Drugs
Descriptive analyses and univariable model results 
are summarized in Appendix Table 9. Final multi-
variable model results are available in Table 6. Sys-
temic HPCIA drugs were less likely to be prescribed 
for vaccinated or insured cats. Although odds of 
prescription were greatest for cats with a respirato-
ry MPC, RCVS-accredited practices were associated 
with increased odds for cats presented for trauma. 
Probability of prescription increased for cats up to 6–9 
years of age, reduced until ≈18 years of age, and in-
creased again thereafter; prescription was more likely 
for male cats 5–14 years of age (Figure 2, panel B). In 
terms of genetic breed, the greatest odds of systemic 
HPCIA prescription were for the Asian group com-
pared with the West Europe group.
Prescription of Topical Antimicrobial Drugs
Descriptive analyses and univariable model results are 
summarized in Appendix Table 10. Final multivariable 
model results are available in Table 7. Topical antimi-
crobial drugs were less likely to be prescribed for in-
sured cats. The effect of age at consultation varied ac-
cording to MPC; probability of prescription decreased 
for pruritic cats until ≈7 years of age, before increasing 
again (Figure 3, panel B). In terms of genetic breed, 
odds were smallest for crossbreeds compared with 
those in the West Europe genetic breed group.
Discussion
We demonstrated frequent prescription of antimi-
crobial drugs, including systemic HPCIAs (particu-
larly in cats), in veterinary practices in Great Britain. 
Considering the importance of HPCIAs in the con-
text of antimicrobial resistance (32), we identified 
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a vital need to learn more about factors potential-
ly driving such prescribing behaviors. We further 
augmented EHR data with a range of external data 
sources to identify key client, animal, and practice-
related risk factors associated with prescription of 
systemic and topical antimicrobial and systemic 
HPCIA drugs; such factors potentially inform key 
antimicrobial stewardship targets of importance to 
companion animal practice.
Regarding client care decision-related factors, 
odds of prescription for systemic antimicrobial and 
HPCIA drugs were significantly lower for vacci-
nated dogs and cats, possibly reflecting perceived or 
actual reduced risk for antimicrobial drug–respon-
sive disease in vaccinated animals. Although most 
companion animal vaccines target viruses, bacterial 
infection secondary to vaccine-preventable viral dis-
ease has been documented (33). Risk avoidance plays 
a major role in antimicrobial drug–prescribing practic-
es (12), potentially prompting more frequent prescrip-
tion for unwell, nonvaccinated animals. We speculate 
that previous engagement with preventive healthcare 
services might select for clients more likely to seek 
veterinary attention earlier or to pursue diagnostic 
options rather than empirical prescription. Regard-
less of what might be driving these trends, the O’Neill 
report recommends that promoting development and 
use of vaccines and alternatives to antibiotics should 
form a key component of efforts to curtail human 
dissemination of antimicrobial resistance (34); our 
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Table 1. Descriptive demographic summary of consultations for sick dogs and cats in study of factors associated with prescription of 
antimicrobial drugs for dogs and cats, United Kingdom, 2014–2016* 
Category Dogs, n = 281,543  Cats, n = 111,139 
Categorical factors   
 Country   
  England 86.6 (81.4–91.9) 88.6 (83.8–93.5) 
  Scotland 6.1 (3.0–9.1) 4.5 (2.1–6.9) 
  Wales 7.4 (2.8–12.0) 7.0 (2.1–6.9) 
 Sex   
  M 51.8 (51.3–52.3) 51.8 (51.3–52.4) 
  F 48.2 (47.7–48.7) 48.2 (47.6–48.7)  
 Neutered 64.6 (63.3–65.9) 82.8 (81.7–84.0) 
 Microchipped 54.4 (52.4–56.3) 37.8 (36.0–39.5) 
 Vaccinated 70.0 (68.6–71.3) 52.7 (51.2–54.1) 
 Insured 33.5 (31.1–35.9) 19.3 (17.3–21.3) 
 Urban 63.8 (59.5–68.1) 70.2 (66.2–74.2) 
 Main presenting complaint   
  Gastroenteric 11.3 (11.0–11.6) 8.3 (8.0–8.7) 
  Respiratory 4.0 (3.8–4.1) 5.5 (5.2–5.8) 
  Pruritus 18.0 (17.3–18.6) 10.3 (9.9–10.7) 
  Trauma 16.8 (16.1–17.5) 17.0 (16.3–17.7) 
  Tumor 6.0 (5.8–6.3) 3.9 (3.6–4.1) 
  Kidney disease 0.7 (0.6–0.8) 2.9 (2.5–3.2) 
  Other unwell 43.3 (42.0–44.6) 52.1 (50.9–53.4) 
 Practice type   
  Mixed 22.7 (15.1–30.3) 18.1 (11.6–24.6) 
  Companion animal 70.6 (62.4–78.8) 76.0 (68.9–83.1) 
  Companion and equine 2.4 (0.7–4.0) 2.3 (0.7–4.0) 
  Companion and large 4.3 (0.4–8.2) 3.5 (0.3–6.8) 
 Accredited 83.9 (77.1–90.6) 83.5 (76.5–90.5) 
 Hospital status 20.2 (14.4–26.0) 20.0 (14.5–25.5) 
 Referral interest 27.9 (20.9–34.9) 27.3 (20.3–34.2) 
 Employed RCVS AVP† 24.5 (17.2–31.7) 26.7 (19.2–34.2) 
 Employed RCVS specialist† 2.5 (0.8–4.2) 1.9 (0.6–3.1) 
Continuous factors   
 Age at consultation   
  Mean 7.1 (7.1–7.2) 9.5 (9.5–9.6) 
  Median (min–max) 7.2 (0–22) 9.7 (0–25.9) 
 Rescaled indices of multiple, mean 0.59 (0.59–0.60) 0.60 (0.60–0.61) 
 rIMD deprivation rank, median (min–max) 0.62 (0.0–1.0) 0.63 (0.0–1.0) 
 Animals/household (30)   
  Mean 0.59 (0.59–0.59) 0.50 (0.49–0.50) 
  Median (min–max) 0.47 (0–6.0) 0.39 (0–3.6) 
 Animals/km2 (30)   
  Mean 399.4 (397.8–401.0) 409.4 (407.0–411.8) 
  Median (min–max) 266 (0–4,360) 288 (0–5,363) 
*Values are % consults (95% CI) except as indicated. AVP, Advanced Veterinary Practitioner; max, maximum; min, minimum; rIMD, rescaled Indices of 
Multiple Deprivation; RCVS, Royal College of Veterinary Surgeons; 
†At least 1 employed veterinary surgeon holding RCVS AVP status, specialist status, or both. 
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Table 2. Results from a multivariable mixed effect logistic regression model assessing the association between a range of categorical 
animal, owner, practitioner and practice-related factors and the probability of prescribing a systemic antimicrobial for dogs, United 
Kingdom, 2014–2016* 
Category β SE OR (95% CI) p value 
Intercept     
 England −0.08 0.08 0.93 (0.80–1.08) NA 
 Scotland −0.06 0.09 0.94 (0.79–1.12) NA 
 Wales −0.13 0.09 0.88 (0.73–1.05) NA 
Categorical factors     
 Initial complaint     
  Gastroenteric NA NA Referent NA 
  Kidney disease −0.38 0.06 0.68 (0.61–0.76) <0.01 
  Other unwell −0.94 0.02 0.39 (0.38–0.40) <0.01 
  Pruritus −0.68 0.02 0.51 (0.49–0.53) <0.01 
  Respiratory 0.10 0.03 1.11 (1.06–1.17) <0.01 
  Trauma −0.89 0.02 0.41 (0.40–0.43) <0.01 
  Tumor −1.18 0.03 0.31 (0.29–0.32) <0.01 
 Neuter status     
  Not neutered NA NA Referent NA 
  Neutered −0.11 0.01 0.90 (0.88–0.92) <0.01 
 Sex     
  F NA NA Referent NA 
  M −0.03 0.01 0.97 (0.95–0.99) 0.01 
 Vaccination status     
  Not vaccinated NA NA Referent NA 
  Vaccinated −0.08 0.01 0.93 (0.90–0.95) <0.01 
 Insurance status     
  Not insured NA NA Referent NA 
  Insured −0.14 0.02 0.87 (0.84–0.90) <0.01 
 Genetic breed group (29)     
  Retriever NA NA Referent NA 
  Ancient/spitz 0.25 0.05 1.28 (1.17–1.40) <0.01 
  Crossbreed 0.06 0.02 1.06 (1.03–1.10) <0.01 
  Herding 0.14 0.03 1.15 (1.09–1.22) <0.01 
  Mastiff-like 0.15 0.02 1.16 (1.11–1.21) <0.01 
  Scent hound 0.10 0.04 1.11 (1.03–1.19) <0.01 
  Sight hound 0.31 0.04 1.36 (1.25–1.48) <0.01 
  Small terrier 0.16 0.02 1.18 (1.13–1.22) <0.01 
  Spaniel 0.16 0.02 1.17 (1.13–1.22) <0.01 
  Toy −0.00 0.03 1.00 (0.94–1.05) 0.92 
  Unclassified 0.11 0.02 1.12 (1.07–1.16) <0.01 
  Unknown 0.09 0.05 1.09 (0.99–1.21) 0.075 
  Working dog 0.19 0.03 1.21 (1.15–1.27) <0.01 
 Practice type     
  Companion animal NA NA Referent NA 
  Mixed 0.14 0.07 1.15 (1.01–1.30) 0.04 
  Companion and equine −0.05 0.15 0.95 (0.71–1.27) 0.73 
  Companion and large 0.13 0.14 1.14 (0.86–1.50) 0.37 
 Accreditation status     
  None NA NA Referent NA 
  >1 accredited site −0.24 0.08 0.79 (0.68–0.92) <0.01 
 Referral interest     
  No NA NA Referent NA 
  Yes −0.10 0.05 0.91 (0.82–1.00) 0.06 
Continuous factors     
 Age      
  Linear −1.12 0.01 0.89 (0.87–0.91) <0.01 
  Quadratic −0.09 0.01 0.92 (0.90–0.93) <0.01 
  Cubic 0.05 0.01 1.05 (1.04–1.07) <0.01 
Interaction terms     
 Insurance status (insured) and age     
  Linear age interaction  0.08 0.02 1.09 (1.04–1.14) <0.01 
  Quadratic age interaction 0.03 0.01 1.03 (1.00–1.06) 0.03 
  Cubic age interaction −0.03 0.01 0.97 (0.95–1.00) 0.02 
*n = 72,436/281,543 sick consultations. Random effect variance ( SD): animal 0.57 ( 0.76), site 0.05 (0.23), practice 0.06 (0.24). Boldface indicates 
significance (p<0.05). NA, not applicable; OR, odds ratio. 
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findings suggest that such recommendations should 
also be considered for companion animals.
Insurance coverage was associated with decreased 
odds of prescription of systemic and topical antimicro-
bial drugs, potentially highlighting veterinary prac-
titioners being more likely to seek a wider range of 
diagnostic options in preference to empirical antibio-
sis for insured animals. However, insured dogs were 
also associated with increased odds of prescription 
of systemic HPCIA drugs. Cost of therapy has been 
shown to influence choice of antimicrobial agent for 
companion animals (17), and HPCIA drugs are anec-
dotally considered a more expensive option than other 
antimicrobial drugs. Hence, our findings might reflect 
increased willingness to prescribe relatively expensive 
antimicrobial drugs for insured dogs.
Although HPCIA drug classification remains un-
der debate, use of HPCIA drugs has formed a focus 
for antimicrobial resistance–related policy (34). Al-
though several classes of HPCIA drugs (e.g., glyco-
peptides, which are not authorized for use in animals) 
are very rarely prescribed for companion animals in 
the United Kingdom (22), prescription of fluoroqui-
nolones and third-generation cephalosporins (partic-
ularly for cats) is relatively common, although current 
antimicrobial drug prescribing guidance strongly dis-
courages such practices (35).
With regard to animal-intrinsic factors, odds for 
prescription of systemic antimicrobial drugs were in-
creased for younger male cats, although the opposite 
was found for dogs. Sex-based variation in risk for 
bacterial infection has been identified (36–38), and cat 
fight–related injuries are a frequently recorded clini-
cal complaint (39), more commonly associated with 
young outdoor-ranging male cats (40). Indeed, we 
found that systemic antimicrobial drugs were more 
commonly prescribed for male cats presented for 
trauma. Furthermore, time of injury is less likely to be 
known for outdoor-ranging cats than for dogs; such 
uncertainty might prompt a more cautious approach 
to prescription of antimicrobial drugs (41).
Other studies have also identified age- or sex-
related variation in risk for antimicrobial resistance 
(36–38). For instance, Radford et al. demonstrated 
decreased probability of systemic antimicrobial pre-
scription with increased patient age (20), potentially 
reflecting increased actual or perceived incidence of 
noncommunicable disease as animals age. This inter-
pretation might partly explain our findings, although 
we noted an exception with prescription of systemic 
HPCIA drugs. For cats, an easy-to-administer (in-
jectable) long-acting third-generation cephalosporin 
formulation is widely used (21–23). Although not 
completely explanatory, our findings may suggest 
that as an animal ages, the client or veterinarian per-
ceives an increased probability of an animal being re-
fractory to an intervention (e.g., oral administration 
of tablets), increasing the likelihood of a prescriber 
choosing easy-to-administer formulations. A previ-
ously identified key influencer of antimicrobial agent 
choice was administration of inappropriate dosages 
as a result of noncompliance (17). Whether the risk 
for antimicrobial resistance posed by a possible un-
derdose of a first-line antimicrobial outweighs the 
risk posed by the labeled dose of a third-line HPCIA 
drug remains unanswered.
As with humans (10,11,13), prescription of sys-
temic antimicrobial drugs for dogs and cats was most 
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Figure 1. Results from 2 
multivariable mixed effect 
logistic regression models 
predicting probability of systemic 
antimicrobial prescription in 
study of factors associated with 
prescription of antimicrobial 
drugs for dogs and cats, United 
Kingdom, 2014–2016.  Modeling 
is shown for sick dogs (A) and 
cats (B) against age of the animal 
at time of consultation, in years. 
For dogs, an interaction term 
considering current insurance 
status has been included; for cats, 
an interaction term considering 
sex has been included. Lines 
refer to predicted probability; 
shading relates to 95% CIs for 
such predictions. Points and triangles are plotted to show original data points expressing the percentage of animals of each relevant age group 
(rounded to 0.5-year groups) for which a systemic antimicrobial was prescribed, according to the dataset analyzed.
Antimicrobial Drugs for Dogs and Cats, UK
commonly associated with respiratory clinical signs. 
Humans having respiratory conditions are often in-
appropriately prescribed antimicrobial drugs; most 
respiratory conditions are viral or noninfectious in 
origin (10). The same has also been shown for com-
panion animals, although bacterial infection second-
ary to primary viral disease has been documented 
(42). Considering these shared patterns, although 
prescribing guidance is available (43), we suggest 
respiratory disease as a pertinent area for further in-
vestigation of One Health antimicrobial stewardship 
intervention methods.
Increased odds of prescription of topical an-
timicrobial drugs was commonly associated with 
the retriever group of dogs, which contains several 
breeds commonly associated with dermatologic dis-
ease (44). This finding and interpretation is plausible, 
suggesting that the breed summarization technique 
used here to combat the modeling issues posed by the 
>250 dog and >50 cat breeds recorded in this dataset 
was useful. However, genetic linkage does not neces-
sarily imply phenotypic similarity. As such, individ-
ual breed-level phenotypes might be responsible for 
conferring variant bacterial infection risk in ways not 
explored, and indeed potentially masked. In future 
analyses, we will aim to identify additional means by 
which breeds can be effectively summarized accord-
ing to shared genotype and phenotype.
Although the individual animal accounted for 
most of the random effect variance seen in this study, 
veterinary-led factors might well yield more readily 
accessible routes toward stewardship. For site ac-
creditation, the voluntary RCVS Practice Standards 
Scheme requires antimicrobial drug use policies, 
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Table 3. Results from a multivariable mixed effect logistic regression model assessing the association between a range of categorical 
animal, owner, practitioner and practice-related factors and the probability of prescribing a systemic highest priority critically important 
antimicrobial drug for dogs, United Kingdom, 2014–2016* 
Category β SE OR (95% CI) p value 
Intercept     
 England −4.77 0.11 0.01 (0.01–0.01) NA 
 Scotland −4.91 0.21 0.01 (0.01–0.01) NA 
 Wales −4.88 0.22 0.01 (0.01–001) NA 
Categorical factors     
 Main presenting complaint     
  Gastroenteric NA NA Referent NA 
  Kidney disease 0.11 0.18 1.12 (0.78–1.60) 0.55 
  Other unwell −0.33 0.06 0.72 (0.64–0.80) <0.01 
  Pruritus −0.23 0.07 0.79 (0.70–0.90) <0.01 
  Respiratory 0.29 0.09 1.33 (1.13–1.57) <0.01 
  Trauma −1.16 0.08 0.31 (0.27–0.37) <0.01 
  Tumor −0.92 0.11 0.40 (0.32–0.49) <0.01 
 Vaccination status     
  Not vaccinated NA NA Referent NA 
  Vaccinated −0.10 0.04 0.91 (0.83–0.99) 0.03 
 Insurance status     
  Not insured NA NA Referent NA 
  Insured 0.15 0.05 1.16 (1.07–1.27) <0.01 
 Genetic breed group (29)     
  Retriever NA NA Referent NA 
  Ancient/spitz 0.12 0.22 1.13 (0.73–1.74) 0.60 
  Crossbreed 0.24 0.08 1.27 (1.09–1.48) <0.01 
  Herding 0.04 0.12 1.04 (0.82–1.32) 0.73 
  Mastiff-like 0.16 0.10 1.17 (0.97–1.43) 0.11 
  Scent hound 0.67 0.13 1.96 (1.52–2.52) <0.01 
  Sight hound 0.43 0.17 1.54 (1.10–2.15) 0.01 
  Small terrier 0.67 0.08 1.96 (1.67–2.29) <0.01 
  Spaniel 0.45 0.08 1.57 (1.33–1.84) <0.01 
  Toy 0.94 0.10 2.56 (2.10–3.12) <0.01 
  Unclassified 0.39 0.09 1.47 (1.24–1.74) <0.01 
  Unknown 0.23 0.22 1.25 (0.81–1.94) 0.31 
  Working dog 0.45 0.11 1.56 (1.27–1.93) <0.01 
Continuous factors     
 Age     
  Linear 0.19 0.04 1.21 (1.12–1.31) <0.01 
  Quadratic −0.06 0.03 0.95 (0.90–0.99) 0.03 
  Cubic 0.04 0.02 1.04 (1.01–1.08) 0.01 
*n = 3,971/281,543 sick consultations. Random effect variance ( SD): animal 3.04 (1.74), site 0.13 (0.36), practice 0.44 (0.66). Significant (p<0.05) 




infection control plans, and established clinical au-
dits (45), and we observed reduced systemic antimi-
crobial prescription odds for dogs in accredited prac-
tices. Although practices seeking accreditation might 
already be more engaged with quality improvement, 
we nevertheless recommend further consideration 
as to whether the RCVS Practice Standards Scheme 
could play a more central role for encouraging stew-
ardship in general and referral practices.
Compared with practices that treat companion 
animals only, mixed species practices were associ-
ated with increased odds of prescription of systemic 
antimicrobial drugs. Veterinary surgeons employed 
in different sectors expressed varied attitudes toward 
antimicrobial resistance (16), a finding perhaps dem-
onstrated on a wide scale in this study. Practices em-
ploying RCVS specialists were also associated with 
reduced odds of prescription of topical antimicro-
bial drugs for dogs, potentially reflecting varied case 
management approaches (46) or caseloads compared 
with general practices.
Considering limitations of this study, although 
we successfully augmented EHRs with a variety of 
data sources, no dataset is infallible. For instance, the 
veterinary surgeon employment record of the RCVS 
Practice Register is updated only on an ad hoc basis. 
It is thus possible that the surveyed veterinary sur-
geon population varied over the 2-year study period 
in ways not captured here. Veterinary practices par-
ticipating in SAVSNET are recruited by convenience 
and might not be representative of the wider UK 
population. Although we found no clear associations 
between IMD or pet population density and prescrip-
tion, the complexities of summarizing IMD across the 
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Figure 2. Results from 2 
multivariable mixed effect 
logistic regression models 
predicting probability of systemic 
highest priority critically 
important antimicrobial (HPCIA) 
prescription in study of factors 
associated with prescription of 
antimicrobial drugs for dogs 
and cats, United Kingdom, 
2014–2016.   Modeling is shown 
for sick dogs (A) and cats (B) 
against age of the animal at 
time of consultation, in years. 
For cats, an interaction term 
considering sex has been 
included. Lines refer to predicted 
probability; shading relates to 
95% CIs for such predictions. 
Points and triangles are plotted to show original data points expressing the percentage of animals of each relevant age group (rounded 
to 0.5-year groups) for which a systemic HPCIA was prescribed, according to the dataset analyzed.
Figure 3. Results from 2 
multivariable mixed effect logistic 
regression models predicting 
probability of topical antimicrobial 
prescription in study of factors 
associated with prescription of 
antimicrobial drugs for dogs and 
cats, United Kingdom, 2014–2016. 
Modeling is shown for sick dogs 
(A) and cats (B) against age of 
the animal at time of consultation, 
in years. For both species, an 
interaction term considering main 
reason for visit (main presenting 
complaint) has been included. 
Lines refer to predicted probability; 
shading relates to 95% CIs for 
such predictions. Points are 
plotted to show original data points expressing the percentage of animals of each relevant age group (rounded to 0.5-year groups) for 
which a topical antimicrobial was prescribed, according to the dataset analyzed.
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Table 5. Results from a multivariable mixed effect logistic regression model assessing the association between a range of categorical 
animal, owner, practitioner and practice-related factors and the probability of prescribing a systemic antimicrobial in cats, United 
Kingdom, 2014–2016* 
Category β SE OR (95% CI) p value 
Intercept     
 England −0.81 0.06 0.45 (0.39–0.50) NA 
 Scotland −0.77 0.10 0.46 (0.38–0.57) NA 
 Wales −0.55 0.12 0.58 (0.46–0.72) NA 
Categorical factors     
 Main presenting complaint     
  Gastroenteric NA NA Referent NA 
  Kidney disease −0.20 0.07 0.82 (0.71–0.94) 0.01 
  Other unwell −0.23 0.04 0.79 (0.73–0.85) <0.01 
  Pruritus −0.37 0.05 0.69 (0.63–0.76) <0.01 
  Respiratory 0.91 0.06 2.48 (2.23–2.77) <0.01 
  Trauma 0.59 0.04 1.80 (1.65–1.97) <0.01 
  Tumor −0.56 0.07 0.57 (0.50–0.65) <0.01 
 Sex     
  F NA NA Referent NA 
  M 0.03 0.05 1.03 (0.93–1.14) 0.59 
 Vaccination status     
  Not vaccinated NA NA Referent NA 
  Vaccinated −0.09 0.02 0.92 (0.89–0.95) <0.01 
 Insurance status     
   Not insured NA NA Referent NA 
   Insured −0.19 0.02 0.82 (0.79–0.86) <0.01 
 Genetic breed group (31)     
  West Europe NA NA Referent NA 
  Asian 0.20 0.05 1.22 (1.10–1.36) <0.01 
  Crossbreed 0.14 0.03 1.16 (1.08–1.23) <0.01 
  Mediterranean 0.36 0.26 1.43 (0.86–2.38) 0.17 
  Unclassified 0.11 0.06 1.11 (0.99–1.24) 0.07 
  Unknown 0.13 0.05 1.14 (1.03–1.26) 0.01 
 Practice type     
  Companion animal NA NA Referent NA 
  Mixed 0.18 0.08 1.20 (1.03–1.39) 0.02 
  Companion and equine −0.01 0.18 1.00 (0.70–1.41) 0.98 
  Companion and large 0.10 0.17 1.10 (0.80–1.53) 0.56 
 Referral interest     
  No NA NA Referent NA 
  Yes −0.08 0.06 0.92 (0.82–1.04) 0.18 
  Employed RCVS AVP†     
  None NA NA Referent NA 
  >1 AVP −0.10 0.07 0.90 (0.79–1.04) 0.16 
Continuous factors     
 Age      
  Linear −0.38 0.02 0.69 (0.66–0.72) <0.01 
  Quadratic −0.08 0.01 0.90 (0.90–0.95) <0.01 
  Cubic 0.10 0.01 1.08 (1.08–1.12) <0.01 
 Cats per km2 (30)     
  Linear −0.02 0.01 0.98 (0.97–1.00) 0.02 
Interaction terms     
 Male sex and age      
  Linear age interaction −0.10 0.03 0.91 (0.85–0.97) <0.01 
  Quadratic age interaction −0.10 0.02 0.91 (0.88–0.94) <0.01 
  Cubic age interaction 0.03 0.02 1.03 (1.00–1.06) 0.11 
 Male sex and main presenting complaint     
  Kidney disease −0.26 0.11 0.77 (0.62–0.96) 0.02 
  Other unwell 0.17 0.05 1.19 (1.07–1.32) <0.01 
  Pruritus 0.10 0.07 1.10 (0.96–1.26) 0.16 
  Respiratory 0.06 0.08 1.06 (0.91–1.23) 0.44 
  Trauma 0.48 0.06 1.62 (1.44–1.82) <0.01 
  Tumor 0.15 0.10 1.16 (0.96–1.40) 0.12 
*n = 36,521/111,139 sick consultations. Random effect variance ( SD): animal 0.50 (0.70), site 0.06 (0.25), practice 0.08 (0.28). Significant (p<0.05) 
results are displayed in boldface. NA, not applicable; OR, odds ratio;  
RCVS, Royal College of Veterinary Surgeons. 
†RCVS Advanced Veterinary Practitioner and/or specialist status. 
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constituent countries of the United Kingdom (47), 
coupled with the relative infancy of pet population 
demographic studies (30), lead us to recommend re-
evaluation as research methods further mature. The 
analyzed population was relatively skewed toward 
less deprived areas; to ascertain whether this finding 
is reflective of the wider UK pet-owning community, 
including the charity and low-income veterinary sec-
tors in future analyses would be warranted. We ad-
vise caution for inferring causal relationships between 
factors and outcome variables explored in this cross-
sectional study; similarly, group-level observations 
might have limited relevance to individual animals. 
More generalized SAVSNET limitations have been 
previously discussed; in brief, quantification of anti-
microbial drug prescription depends on practitioners 
charging for antimicrobial drugs, and analyzed prac-
tices were recruited by convenience (22,30).
In conclusion, we demonstrated the value of 
using veterinary EHRs collected from a cohort of 
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Table 6. Results from a multivariable mixed effect logistic regression model assessing the association between a range of categorical 
animal, owner, practitioner and practice-related factors and the probability of prescribing a systemic highest priority critically important 
antimicrobial drug for cats, United Kingdom, 2014–2016* 
Category β SE OR (95% CI) p value 
Intercept     
 England −2.79 0.21 0.06 (0.04–0.09) NA 
 Scotland −2.74 0.24 0.07 (0.04–0.10) NA 
 Wales −2.55 0.24 0.08 (0.05–0.12) NA 
Categorical factors     
 Main presenting complaint NA NA Referent NA 
  Gastroenteric 0.55 0.25 1.74 (1.08–2.82) 0.02 
  Kidney disease 0.59 0.12 1.80 (1.43–2.26) <0.01 
  Other unwell 1.08 0.13 2.95 (2.28–3.81) <0.01 
  Pruritus 1.50 0.14 4.47 (3.41–5.85) <0.01 
  Respiratory 1.06 0.12 2.89 (2.27–3.67) <0.01 
  Trauma 0.38 0.18 1.46 (1.04–2.03) 0.03 
  Tumor NA NA Referent NA 
 Sex 0.12 0.03 1.13 (1.07–1.19) <0.01 
  F NA NA Referent NA 
  M −0.06 0.02 0.95 (0.91–0.98) <0.01 
 Vaccination status NA NA Referent NA 
  Not vaccinated −0.14 0.03 0.87 (0.83–0.92) <0.01 
  Vaccinated NA NA Referent NA 
 Insurance status 0.05 0.03 1.05 (1.00–1.11) 0.06 
   Not insured NA NA Referent NA 
   Insured 0.21 0.07 1.23 (1.08–1.40) <0.01 
 Genetic breed group (31) 0.14 0.04 1.16 (1.06–1.26) <0.01 
  West Europe 0.11 0.32 1.12 (0.59–2.11) 0.73 
  Asian 0.14 0.07 1.15 (1.00–1.33) 0.06 
  Crossbreed 0.12 0.06 1.12 (0.99–1.27) 0.07 
 Accreditation status     
  Not accredited NA NA Referent NA 
  >1 accredited site 0.10 0.22 1.10 (0.72–1.69) 0.65 
Continuous factors     
 Age     
  Linear −0.23 0.03 0.80 (0.76–0.85) <0.01 
  Quadratic −0.13 0.02 0.88 (0.85–0.90) <0.01 
  Cubic 0.13 0.01 1.14 (1.11–1.17) <0.01 
Interaction terms     
 Main presenting complaint and accreditation 
 (accredited site)     
  Kidney disease 0.23 0.26 1.26 (0.76–2.08) 0.37 
  Other unwell 0.21 0.13 1.23 (0.96–1.58) 0.10 
  Pruritus 0.00 0.14 1.00 (0.76–1.32) 1.00 
  Respiratory 0.23 0.15 1.26 (0.94–1.69) 0.12 
  Trauma 0.64 0.13 1.90 (1.46–2.47) <0.01 
  Tumor 0.19 0.19 1.21 (0.83–1.75) 0.32 
 Male sex and age     
  Linear age interaction  −0.06 0.04 0.95 (0.87–1.02) 0.17 
  Quadratic age interaction −0.09 0.02 0.91 (0.87–0.95) <0.01 
  Cubic age interaction  0.02 0.02 1.02 (0.98–1.06) 0.32 
*n = 19,018/111,139 sick consultations. Random effect variance ( SD): animal 0.68 (0.82, site 0.13 (0.36), practice 0.44 (0.66). Significant (p<0.05) 
results are displayed in boldface. NA, not applicable; OR, odds ratio. 
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Table 7. Results from a multivariable mixed effect logistic regression model assessing the association between a range of categorical 
animal, owner, practitioner and practice-related factors and the probability of prescribing a topical antimicrobial in cats, United 
Kingdom, 2014–2016* 
Category β SE OR (95% CI) p value 
Intercept     
 England −3.98 0.17 0.02 (0.01–0.03) -NA 
 Scotland −3.94 0.19 0.02 (0.01–0.03) NA 
 Wales −3.91 0.19 0.02 (0.01–0.03) NA 
Categorical factors     
 Main presenting complaint     
  Gastroenteric NA NA Referent NA 
  Kidney disease −0.98 0.50 0.38 (0.14–1.00) 0.05 
  Other unwell 1.79 0.16 5.96 (4.37–8.12) <0.01 
  Pruritus 2.13 0.16 8.37 (6.09–11.51) <0.01 
  Respiratory 1.21 0.18 3.36 (2.35–4.82) <0.01 
  Trauma 1.34 0.17 3.82 (2.76–5.28) <0.01 
  Tumor 0.38 0.25 1.46 (0.90–2.36) 0.12 
 Sex     
  F NA NA Referent NA 
  M 0.05 0.03 1.05 (1.00–1.11) 0.06 
 Neutered status     
  Not neutered NA NA Referent NA 
  Neutered −0.06 0.04 0.94 (0.88–1.01) 0.09 
 Insurance status     
  Not insured NA NA Referent NA 
  Insured −0.13 0.04 0.88 (0.82–0.95) <0.01 
 Genetic breed group (31)     
  West Europe NA NA Referent NA 
  Asian −0.14 0.09 0.87 (0.73–1.03) 0.09 
  Crossbreed −0.50 0.05 0.61 (0.55–0.67) <0.01 
  Mediterranean −0.40 0.50 0.67 (0.25–1.78) 0.42 
  Unclassified −0.24 0.09 0.79 (0.66–0.95) 0.01 
  Unknown −0.43 0.08 0.65 (0.56–0.77) <0.01 
 Referral interest     
  No NA NA Referent NA 
  Yes 0.08 0.05 1.08 (0.98–1.19) 0.11 
Continuous factors     
 Age      
  Linear 0.08 0.26 1.09 (0.65–1.82) 0.75 
  Quadratic −0.12 0.14 0.89 (0.68–1.17) 0.40 
  Cubic −0.14 0.14 0.87 (0.66–1.15) 0.34 
Interaction terms     
 Main presenting complaint and age     
  Linear age interaction     
   Kidney disease 1.14 0.68 3.11 (0.82–11.84) 0.10 
   Other unwell −0.61 0.27 0.54 (0.32–0.91) 0.02 
   Pruritus 0.18 0.27 1.19 (0.70–2.03) 0.52 
   Respiratory −0.34 0.31 0.71 (0.39–1.29) 0.26 
   Trauma 0.07 0.28 1.07 (0.62–1.85) 0.81 
   Tumor −0.07 0.38 0.93 (0.44–1.95) 0.85 
  Quadratic age interaction     
   Kidney disease  0.52 0.32 1.69 (0.89–3.18) 0.11 
   Other unwell  0.16 0.14 1.17 (0.89–1.53) 0.26 
   Pruritus  0.42 0.14 1.52 (1.15–2.02) <0.01 
   Respiratory  0.26 0.16 1.29 (0.95–1.77) 0.11 
   Trauma  0.22 0.15 1.24 (0.93–1.65) 0.14 
   Tumor  0.16 0.20 1.18 (0.80–1.73) 0.41 
  Cubic age interaction      
   Kidney disease  −0.51 0.33 0.60 (0.31–1.16) 0.13 
   Other unwell  0.14 0.14 1.15 (0.87–1.52) 0.33 
   Pruritus  0.04 0.15 1.04 (0.78–1.38) 0.81 
   Respiratory  −0.03 0.16 0.97 (0.70–1.33) 0.84 
   Trauma  0.06 0.15 1.06 (0.79–1.42) 0.70 
   Tumor  0.10 0.19 1.10 (0.75–1.61) 0.62 
*n = 6,769/111,139 sick consultations. Random effect variance ( SD): animal 0.82 (0.90,) site 0.02 (0.15), practice 0.03 (0.16). Significant (p<0.05) 
results are displayed in boldface. OR, odds ratio; RCVS, Royal College of Veterinary Surgeons. 
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veterinary practices to identify a range of factors 
associated with prescription of antimicrobial drugs 
for dogs and cats. Although factors influencing 
decision-making remain multifactorial and com-
plex, our findings suggest that gathering clinical 
evidence surrounding respiratory disease might 
be of value to stewardship. Preventive healthcare 
could also play a role in stewardship and should 
form the basis of client-targeted health messaging, 
as should the RCVS Practice Standards Scheme for 
veterinary practitioners.
Acknowledgments
We thank data providers in veterinary practice  
(VetSolutions, Teleos, CVS, and other practitioners) and in 
veterinary diagnostics, without whose support and  
participation this research would not have been possible. 
We are especially grateful for the help and support  
provided by SAVSNET team members Susan Bolan, 
Bethaney Brant, and Steven Smyth.
This work was funded by The Veterinary Medicines  
Directorate (VM0520), the University of Liverpool, and 
SAVSNET. We are grateful for the support and major 
funding from the Biotechnology and Biological Sciences 
Research Council and the British Small Animal Veterinary 
Association, as well as for sponsorship from the Animal 
Welfare Foundation.
About the Author 
Dr. Singleton is a veterinary surgeon working as a  
postdoctoral research associate at the University of  
Liverpool. His research interests are observational and 
interventional epidemiology, health informatics, and 
antimicrobial resistance within a One Health framework. 
Much of his work has used electronic health record data 
collated by SAVSNET. 
References
  1. Rantala M, Lahti E, Kuhalampil J, Pesonen S, Järvinen AK, 
Saijonmaa-Koulumies, et al. Antimicrobial resistance in 
Staphylococcus spp., Escherichia coli and Enterococcus spp. in 
dogs given antibiotics for chronic dermatological disorders, 
compared with non-treated control dogs. Acta Vet Scand. 
2004;45:37–45. https://doi.org/10.1186/1751-0147-45-37
  2. Trott DJ, Filippich LJ, Bensink JC, Downs MT, McKenzie 
SE, Townsend KM, et al. Canine model for investigating the 
impact of oral enrofloxacin on commensal coliforms and 
colonization with multidrug-resistant Escherichia coli.  
J Med Microbiol. 2004;53:439–43. https://doi.org/10.1099/
jmm.0.05473-0
  3. Cantón R, Bryan J. Global antimicrobial resistance: from 
surveillance to stewardship. Part 1: surveillance and risk 
factors for resistance. Expert Rev Anti Infect Ther Actions. 
2012;10:1269–71. https://doi.org/10.1586/eri.12.120 
  4. Cuny C, Wieler LH, Witte W. Livestock-associated MRSA: 
the impact on humans. Antibiotics (Basel). 2015;4:521–43. 
https://doi.org/10.3390/antibiotics4040521
  5. Zhang X-F, Doi Y, Huang X, Li HY, Zhong LL, Zeng KJ,  
et al. Possible transmission of mcr-1-harboring Escherichia coli 
between companion animals and human. Emerg Infect Dis. 
2016;22:1679–81. https://doi.org/10.3201/eid2209.160464
  6. Guardabassi L, Schwarz S, Lloyd DH. Pet animals as 
reservoirs of antimicrobial-resistant bacteria. J Antimicrob 
Chemother. 2004;54:321–32. https://doi.org/10.1093/jac/
dkh332
  7. Guardabassi L, Loeber ME, Jacobson A. Transmission of 
multiple antimicrobial-resistant Staphylococcus intermedius 
between dogs affected by deep pyoderma and their owners. 
Vet Microbiol. 2004;98:23–7. https://doi.org/10.1016/ 
j.vetmic.2003.09.021
  8. Johnson JR, Johnston B, Clabots CR, Kuskowski MA,  
Roberts E, DebRoy C. Virulence genotypes and phylogenetic 
background of Escherichia coli serogroup O6 isolates from 
humans, dogs, and cats. J Clin Microbiol. 2008;46:417–22. 
https://doi.org/10.1128/JCM.00674-07
  9. World Health Organization. Global action plan on antimicrobial 
resistance [cited 2001 Jun 16].  http://apps.who.int/iris/ 
bitstream/handle/10665/193736/9789241509763_eng.pdf
10. Altiner A, Wilm S, Wegscheider K, Sielk M, Brockmann S, 
Fuchs A, et al. Fluoroquinolones to treat uncomplicated acute 
cough in primary care: predictors for unjustified prescrib-
ing of antibiotics. J Antimicrob Chemother. 2010;65:1521–5. 
https://doi.org/10.1093/jac/dkq151
11. Hawker JI, Smith S, Smith GE, Morbey R, Johnson AP,  
Fleming DM, et al. Trends in antibiotic prescribing in  
primary care for clinical syndromes subject to national  
recommendations to reduce antibiotic resistance, UK 
1995–2011: analysis of a large database of primary care 
consultations. J Antimicrob Chemother. 2014;69:3423–30. 
https://doi.org/10.1093/jac/dku291
12. McCullough AR, Rathbone J, Parekh S, Hoffmann TC,  
Del Mar CB. Not in my backyard: a systematic review of 
clinicians’ knowledge and beliefs about antibiotic resistance. 
J Antimicrob Chemother. 2015;70:2465–73. https://doi.org/ 
10.1093/jac/dkv164
13. McKay R, Mah A, Law MR, McGrail K, Patrick DM.  
Systematic review of factors associated with antibiotic  
prescribing for respiratory tract infections. Antimicrob  
Agents Chemother. 2016;60:4106–18. https://doi.org/ 
10.1128/AAC.00209-16
14. Welsh CE, Parkin TDH, Marshall JF. Use of large-scale  
veterinary data for the investigation of antimicrobial 
prescribing practices in equine medicine. Equine Vet J. 
2017;49:425–32. https://doi.org/10.1111/evj.12638
15. Hughes LA, Williams N, Clegg P, Callaby R, Nuttall T, 
Coyne K, et al. Cross-sectional survey of antimicrobial 
prescribing patterns in UK small animal veterinary practice. 
Prev Vet Med. 2012;104:309–16. https://doi.org/10.1016/ 
j.prevetmed.2011.12.003
16. De Briyne N, Atkinson J, Pokludová L, Borriello SP, Price S. 
Factors influencing antibiotic prescribing habits and use of 
sensitivity testing amongst veterinarians in Europe. Vet Rec. 
2013;173:475. https://doi.org/10.1136/vr.101454
17. Mateus AL, Brodbelt DC, Barber N, Stärk KD. Qualitative  
study of factors associated with antimicrobial usage in  
seven small animal veterinary practices in the UK. Prev  
Vet Med. 2014;117:68–78. https://doi.org/10.1016/ 
j.prevetmed.2014.05.007
18. O’Neill DG, Church DB, McGreevy PD, Thomson PC,  
Brodbelt DC. Approaches to canine health surveillance.  
1790 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 8, August 2020
Antimicrobial Drugs for Dogs and Cats, UK
Canine Genet Epidemiol. 2014;1:2. https://doi.org/ 
10.1186/2052-6687-1-2
19. Sánchez-Vizcaíno F, Jones PH, Menacere T, Heayns B, 
Wardeh M, Newman J, et al. Small animal disease  
surveillance. Vet Rec. 2015;177:591–4. https://doi.org/ 
10.1136/vr.h6174
20. Radford AD, Noble PJ, Coyne KP, Gaskell RM, Jones PH, 
Bryan JG, et al. Antibacterial prescribing patterns in small 
animal veterinary practice identified via SAVSNET: the 
Small Animal Veterinary Surveillance Network. Vet Rec. 
2011;169:310. https://doi.org/10.1136/vr.d5062
21. Buckland EL, O’Neill D, Summers J, Mateus A, Church D, 
Redmond L, et al. Characterisation of antimicrobial usage in 
cats and dogs attending UK primary care companion animal 
veterinary practices. Vet Rec. 2016;179:489. https://doi.org/ 
10.1136/vr.103830
22. Singleton DA, Sánchez-Vizcaíno F, Dawson S, Jones PH, 
Noble PJM, Pinchbeck GL, et al. Patterns of antimicrobial 
agent prescription in a sentinel population of canine and 
feline veterinary practices in the United Kingdom. Vet J. 
2017;224:18–24. https://doi.org/10.1016/j.tvjl.2017.03.010
23. Burke S, Black V, Sánchez-Vizcaíno F, Radford A, Hibbert A, 
Tasker S. Use of cefovecin in a UK population of cats  
attending first-opinion practices as recorded in electronic 
health records. J Feline Med Surg. 2017;19:687–92.  
https://doi.org/10.1177/1098612X16656706
24. World Health Organization. WHO list of critically important 
antimicrobials (WHO CIA list) [cited 2001 Jun 19].  
https://www.who.int/foodsafety/areas_work/ 
antimicrobial-resistance/cia
25. German AJ, Halladay LJ, Noble PJ. First-choice therapy for 
dogs presenting with diarrhoea in clinical practice. Vet Rec. 
2010;167:810–4. https://doi.org/10.1136/vr.c4090
26. Jones PH, Dawson S, Gaskell RM, Coyne KP, Tierney A, 
Setzkorn C, et al. Surveillance of diarrhoea in small animal 
practice through the Small Animal Veterinary Surveillance 
Network (SAVSNET). Vet J. 2014;201:412–8. https://doi.org/ 
10.1016/j.tvjl.2014.05.044
27. Day MJ, Horzinek MC, Schultz RD, Squires RA; Vaccination 
Guidelines Group (VGG) of the World Small Animal  
Veterinary Association (WSAVA). WSAVA guidelines for the 
vaccination of dogs and cats. J Small Anim Pract. 2016;57: 
E1–45. https://doi.org/10.1111/jsap.2_12431
28. Sánchez-Vizcaíno F, Noble PM, Jones PH, Menacere T, 
Buchan I, Reynolds S, et al. Demographics of dogs, cats, 
and rabbits attending veterinary practices in Great Britain 
as recorded in their electronic health records. BMC Vet Res. 
2017;13:218. https://doi.org/10.1186/s12917-017-1138-9
29. vonholdt BM, Pollinger JP, Lohmueller KE, Han E,  
Parker HG, Quignon P, et al. Genome-wide SNP and  
haplotype analyses reveal a rich history underlying dog 
domestication. Nature. 2010;464:898–902. https://doi.org/ 
10.1038/nature08837
30. Aegerter J, Fouracre D, Smith GC. A first estimate of the 
structure and density of the populations of pet cats and  
dogs across Great Britain. PLoS One. 2017;12:e0174709.  
https://doi.org/10.1371/journal.pone.0174709
31. Lipinski MJ, Froenicke L, Baysac KC, Billings NC,  
Leutenegger C, Levy AM, et al. The ascent of cat breeds: 
genetic evaluations of breeds and worldwide random-bred 
populations. Genomics. 2008;91:12–1. https://doi.org/ 
10.1016/j.ygeno.2007.10.009
32. World Health Organization. Critically important  
antimicrobials for human medicine: 5th revision 2016 [cited 
2001 Apr 16]. http://apps.who.int/iris/bitstream/ 
handle/10665/255027/9789241512220-eng.pdf
33. Goddard A, Leisewitz AL. Canine parvovirus. Vet Clin 
North Am Small Anim Pract. 2010;40:1041–53. 
https://doi.org/10.1016/j.cvsm.2010.07.007
34. O’Neill J. Review on antimicrobial resistance: tackling  
drug-resistant infections globally [cited 2015 Dec 15].  
http://amr-review.org/home
35. British Small Animal Veterinary Association. BSAVA/ 
SAMSoc guide to responsible use of antibacterials: PROTECT 
ME [cited 2011 Nov 18].  https://www.bsavalibrary.com/
content/book/10.22233/9781910443644
36. Hall JL, Holmes MA, Baines SJ. Prevalence and  
antimicrobial resistance of canine urinary tract pathogens. 
Vet Rec. 2013;173:549. https://doi.org/10.1136/vr.101482
37. Hernandez J, Bota D, Farbos M, Bernardin F, Ragetly G, 
Médaille C. Risk factors for urinary tract infection with  
multiple drug-resistant Escherichia coli in cats. J Feline 
Med Surg. 2014;16:75–81. https://doi.org/10.1177/ 
1098612X13504407
38. Huerta B, Maldonado A, Ginel PJ, Tarradas C,  
Gómez-Gascón L, Astorga RJ, et al. Risk factors associated 
with the antimicrobial resistance of staphylococci in canine 
pyoderma. Vet Microbiol. 2011;150:302–8. https://doi.org/ 
10.1016/j.vetmic.2011.02.002
39. O’Neill DG, Church DB, McGreevy PD, Thomson PC,  
Brodbelt DC. Prevalence of disorders recorded in cats  
attending primary-care veterinary practices in England. Vet 
J. 2014;202:286–91. https://doi.org/10.1016/j.tvjl.2014.08.004
40. Chhetri BK, Berke O, Pearl DL, Bienzle D. Comparison of 
risk factors for seropositivity to feline immunodeficiency  
virus and feline leukemia virus among cats: a case-case 
study. BMC Vet Res. 2015;11:30. https://doi.org/10.1186/
s12917-015-0339-3
41. Quinn JV, Polevoi SK, Kohn MA. Traumatic lacerations: 
what are the risks for infection and has the ‘golden period’ of 
laceration care disappeared? Emerg Med J. 2014;31:96–100. 
https://doi.org/10.1136/emermed-2012-202143
42.  Feline bordetellosis: challenge and vaccine studies. Vet Rec. 
1993;133:260–3. https://doi.org/10.1136/vr.133.11.260
43. Lappin MR, Blondeau J, Boothe D, Breitschwerdt EB, 
Guardabassi L, Lloyd DH, et al. Antimicrobial use guidelines 
for treatment of respiratory tract disease in dogs and cats: 
Antimicrobial Guidelines Working Group of the Interna-
tional Society for Companion Animal Infectious Diseases.  
J Vet Intern Med. 2017;31:279–94. https://doi.org/10.1111/
jvim.14627
44. Nuttall T, Uri M, Halliwell R. Canine atopic dermatitis -  
what have we learned? Vet Rec. 2013;172:201–7.  
https://doi.org/10.1136/vr.f1134
45. Royal College of Veterinary Surgeons. Practice Standards 
Scheme [cited 2001 Dec 17]. https://www.rcvs.org.uk/
setting-standards/practice-standards-scheme
46. Pleydell EJ, Souphavanh K, Hill KE, French NP, Prattley DJ. 
Descriptive epidemiological study of the use of antimicrobial 
drugs by companion animal veterinarians in New Zealand. 
N Z Vet J. 2012;60:115–22. https://doi.org/10.1080/00480169
.2011.643733
47. Abel GA, Barclay ME, Payne RA. Adjusted indices of  
multiple deprivation to enable comparisons within and 
between constituent countries of the UK including an  
illustration using mortality rates. BMJ Open. 2016;6:e012750. 
https://doi.org/10.1136/bmjopen-2016-012750
Address for correspondence: David A. Singleton, University of 
Liverpool, Epidemiology and Population Health, Chester High 
Rd, Neston CH64 7TE, UK; email: D.A.Singleton@liverpool.ac.uk
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 8, August 2020 1791
